Centene (CNC)
(Delayed Data from NYSE)
$74.81 USD
+0.48 (0.65%)
Updated May 3, 2024 04:00 PM ET
After-Market: $74.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.81 USD
+0.48 (0.65%)
Updated May 3, 2024 04:00 PM ET
After-Market: $74.81 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Centene Corporation is a well-diversified, multi-national healthcare company that primarily provides a set of services to the government sponsored healthcare programs. The company serves the under-insured and uninsured individuals through member-focused services. It is also engaged in providing education and outreach programs to inform and assist members in accessing quality, appropriate healthcare services. Centene is now a $100-billion plus enterprise catering healthcare services to more than 24 million members across 50 states. The recent acquisition of WellCare Health leveraged the company’s position as the largest Medicaid managed care organization in the country. The combined entity now has 22 million members. In 2019, the company retained its market-leading position nationwide, serving 1.8 million exchange members across 20 states at the year-end.
Centene (CNC) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Centene (CNC) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Highly Ranked Stocks to Watch as Earnings Approach
by Shaun Pruitt
Set to release their quarterly results on Tuesday, February 6, here are several standout stocks that investors will certainly want to pay attention to.
Cigna (CI) Q4 Earnings Beat on Membership Growth, Dividend Up
by Zacks Equity Research
Cigna (CI) expects adjusted revenues to register a minimum growth of 20.3% from the 2023 reported figure.
Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?
by Zacks Equity Research
Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.
Stay Ahead of the Game With Centene (CNC) Q4 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Centene (CNC), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Molina (MOH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Centene (CNC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Centene (CNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CNC vs. HUM: Which Stock Is the Better Value Option?
by Zacks Equity Research
CNC vs. HUM: Which Stock Is the Better Value Option?
Are Investors Undervaluing Centene (CNC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Humana (HUM) Q4 Earnings Miss on Higher Costs, '25 Target Pulled
by Zacks Equity Research
Humana (HUM) expects 2024 revenues to increase to around $113 billion.
Zacks.com featured highlights General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank
by Zacks Equity Research
General Motors, Cemex, Centene, Qifu Technology and Deutsche Bank have been highlighted in this Screen of The Week article.
Elevance (ELV) Q4 Earnings Beat on Premium Growth, Dividend Hiked
by Zacks Equity Research
Elevance Health (ELV) expects 2024 premium revenues to remain in line with the 2023 level.
5 Promising Price-to-Book Value Stocks to Buy Now
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. General Motors Company (GM), Cemex (CX), Centene (CNC), Qifu Technology (QFIN) and Deutsche Bank Aktiengesellschaft (DB) are some such stocks.
Focus on These 4 Low P/CF Stocks to Maximize Returns in 2024
by Sumit Singh
Value investing is essentially about selecting stocks that are cheap but fundamentally sound. PVH Corp. (PVH), Centene (CNC), General Motors (GM) and Graphic Packaging (GPK) boast a low P/CF ratio.
Centene (CNC) Chosen to Serve New Hampshire's Medicaid Members
by Zacks Equity Research
Centene's (CNC) subsidiary has been selected by the DHHS to serve the diversified health needs of members of New Hampshire's Medicaid program and thereby, earn more members.
Can Higher Costs Affect Elevance Health's (ELV) Q4 Earnings?
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter results are likely to reflect higher premiums and product revenues.
Molina Healthcare, Inc (MOH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Molina (MOH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?
by Zacks Equity Research
Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.
Why You Should Retain Elevance (ELV) Stock in Your Portfolio
by Zacks Equity Research
Elevance's (ELV) Carelon unit is expected to benefit from improving performance in the Behavioral Health business and post-acute care services.
Centene (CNC) Sells Circle Health to Boost Managed Care Business
by Zacks Equity Research
Centene (CNC) concludes the divestiture of Circle Health to expand its core Managed Care business. Additionally, its plan members will enjoy continued access to Kroger's pharmacy network in 2024.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UnitedHealth (UNH) Stock Declines 3.4% on High Medical Costs
by Zacks Equity Research
As more seniors resume elective procedures, claims rise in UnitedHealth's (UNH) Medicare Advantage business.
UnitedHealth Group (UNH) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 3.01% and 2.57%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can UnitedHealth's (UNH) UnitedHealthcare Unit Aid Q4 Earnings?
by Zacks Equity Research
UnitedHealth's (UNH) fourth-quarter results are expected to benefit from an increase in UnitedHealthcare's Medicare & Retirement revenues as well as the number of people it served.
Brookdale (BKD) Sees Growth in December 2023 Occupancy Volumes
by Zacks Equity Research
Brookdale (BKD) witnesses a continuous streak of 26 months of year-over-year increases in the weighted average occupancy level.